Heart Block and Empirical Therapy After Transcatheter Closure of Perimembranous Ventricular Septal Defect

Overview

Journal Catheter Cardiovasc Interv

Specialty Cardiology & Vascular Diseases

Date 2005 Oct 11

PMID 16216027

Citations 31

Authors

William C L Yip

Frank Zimmerman

Ziyad M Hijazi

Affiliations

Soon will be listed here.

Abstract

Two patients with perimembranous ventricular septal defects (VSDs) and inlet extension have undergone uncomplicated transcatheter device closure using the Amplatzer membranous VSD device. Both patients developed complete heart block 2-4 days from the closure. Both patients responded well to high-dose intravenous therapy with steroids and high-dose oral anti-inflammatory aspirin. Both patients remain in normal sinus rhythm 8 weeks and 10 months, respectively, from the episode.

Citing Articles

Diagnosis and Management of Ventricular Septal Defects.

Rao P Rev Cardiovasc Med. 2024; 25(11):411.

PMID: 39618865 PMC: 11607469. DOI: 10.31083/j.rcm2511411.

Biodegradable Cardiac Occluder with Surface Modification by Gelatin-Peptide Conjugate to Promote Endogenous Tissue Regeneration.

Kong P, Liu X, Li Z, Wang J, Gao R, Feng S Adv Sci (Weinh). 2023; 11(2):e2305967.

PMID: 37984880 PMC: 10787076. DOI: 10.1002/advs.202305967.

Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects.

Song J Korean Circ J. 2023; 53(3):134-150.

PMID: 36914603 PMC: 10011220. DOI: 10.4070/kcj.2022.0336.

A fully biodegradable polydioxanone occluder for ventricle septal defect closure.

Li Z, Kong P, Liu X, Feng S, Ouyang W, Wang S Bioact Mater. 2023; 24:252-262.

PMID: 36632501 PMC: 9813538. DOI: 10.1016/j.bioactmat.2022.12.018.

Short- and Long-term Outcome After Interventional VSD Closure: A Single-Center Experience in Pediatric and Adult Patients.

Bergmann M, Germann C, Nordmeyer J, Peters B, Berger F, Schubert S Pediatr Cardiol. 2020; 42(1):78-88.

PMID: 33009919 PMC: 7864847. DOI: 10.1007/s00246-020-02456-2.